Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R

International Journal of Oncology

Volumn 29, Issue 2, 2006, Pages 445-451

  Fujiwara, Masachika ^a   Kamma, Hiroshi ^b,c   Wu, Wenwen ^b   Yano, Yukiko ^b   Homma, Shinsuke ^b   Satoh, Hiroaki ^b  

^a Kensei General Hospital   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c KYORIN UNIVERSITY   (Japan)

Author keywords

Adrenocortical carcinoma; ALT; H295R; Telomere

Indexed keywords

OLIGONUCLEOTIDE; TELOMERASE;

ADRENAL CORTEX TUMOR; ARTICLE; CARCINOMA; CELL NUCLEUS; CHEMISTRY; FLUORESCENCE IN SITU HYBRIDIZATION; HELA CELL; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE; TUMOR CELL LINE; ULTRASTRUCTURE;

ADRENAL CORTEX NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL NUCLEUS; HELA CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASMS; OLIGONUCLEOTIDES; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TELOMERE;

EID: 39049182810     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.2.445     Document Type: Article

References (38)

1. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791, 1997.
2. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW and Villeponteau B: The RNA component of human telomerase. Science 269: 1236-1241, 1995.
3. Reddel RR, Bryan TM, Colgin LM, Perrem KT and Yeager TR: Alternative lengthening of telomeres in human cells. Radiat Res 155: 194-200, 2001.
4. Henson JD, Neumann AA, Yeager TR and Reddel RR: Alternative lengthening of telomeres in mammalian cells. Oncogene 21: 598-610, 2002.
5. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA and Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3: 1271-1274, 1997.
6. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA and La Rocca RV: Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 50: 5488-5496, 1990.
7. Rainey WE, Bird IM, Sawetawan C, Hanley NA, McCarthy JL, McGee EA, Wester R and Mason JI: Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. J Clin Endocrinol Metab 77: 731-737, 1993.
8. Rainey WE, Bird IM and Mason JI: The H295R cell line: a pluripotent model for human adrenocortical studies. Mol Cell Endocrinol 100: 45-50, 1994.
9. Bryan TM, Englezou A, Gupta J, Bacchetti S and Reddel RR: Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14: 4240-4248, 1995.
10. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR and Reddel RR: Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59: 4175-4179, 1999.
11. Dunham MA, Neumann AA, Fasching CL and Reddel RR: Telomere maintenance by recombination in human cells. Nat Genet 26: 447-450, 2000.
12. Opitz OG, Suliman Y, Hahn WC, Harada H, Blum HE and Rustgi AK: Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest 108: 725-732, 2001.
13. Hamasaki M, Kamma H, Wu W, Kaneko S, Fujiwara M, Satoh H, Haraoka S, Kikuchi M and Shirakusa T: Expression of hnRNP B1 in four major histological types of lung cancers. Anticancer Res 21: 979-984, 2001.
14. Tani H, Ohshima K, Haraoka S, Hamasaki M, Kamma H, Ikeda S and Kikuchi M: Overexpression of heterogeneous nuclear ribonucleoprotein B1 in lymphoproliferative disorders: high expression in cells of follicular center origin. Int J Oncol 21: 957-963, 2002.
15. Snead DR, Perunovic B, Cullen N, Needham M, Dhillon DP, Satoh H and Kamma H: hnRNP B1 expression in benign and malignant lung disease. J Pathol 200: 88-94, 2003.
16. Ohshima K, Karube K, Shimazaki K, Kamma H, Suzumiya J, Hamasaki M and Kikuchi M: Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma 44: 1339-1346, 2003.
17. Satoh H, Kamma H, Ishikawa H, Horiguchi H, Fujiwara M, Yamashita YT, Ohtsuka M and Sekizawa K: Expression of hnRNP A2/B1 proteins in human cancer cell lines. Int J Oncol 16: 763-767, 2000.
18. McKay SJ and Cooke H: A protein which specifically binds to single stranded TTAGGGn repeats. Nucleic Acids Res 20: 1387-1391, 1992.
19. Ford LP, Wright WE and Shay JW: A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation. Oncogene 21: 580-583, 2002.
20. Kamma H, Fujimoto M, Fujiwara M, Matsui M, Horiguchi H, Hamasaki M and Satoh H: Interaction of hnRNP A2/B1 isoforms with telomeric ssDNA and the in vitro function. Biochem Biophys Res Commun 280: 625-630, 2001.
21. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
22. Kim NW and Wu F: Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 25: 2595-2597, 1997.
23. Ulaner GA, Hu JF, Vu TH, Giudice LC and Hoffman AR: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 58: 4168-4172, 1998.
24. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y and Narayanan R: Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 58: 622-625, 1998.
25. Yamada K, Yajima T, Yagihashi A, Kobayashi D, Koyanagi Y, Asanuma K, Yamada M, Moriai R, Kameshima H and Watanabe N: Role of human telomerase reverse transcriptase and telomeric-repeat binding factor proteins 1 and 2 in human hematopoietic cells. Jpn J Cancer Res 91: 1278-1284, 2000.
26. Howe D and Lynas C: The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 86: 563-569, 2001.
27. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR and Jefferson RA: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 6: 2011-2019, 1997.
28. Kamma H, Satoh H, Matusi M, Wu WW, Fujiwara M and Horiguchi H: Characterization of hnRNP A2 and B1 using monoclonal antibodies: intracellular distribution and metabolism through cell cycle. Immunol Lett 76: 49-54, 2001.
29. Bryan TM, Englezou A, Dunham MA and Reddel RR: Telomere length dynamics in telomerase-positive immortal human cell populations. Exp Cell Res 239: 370-378, 1998.
30. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR and Ladanyi M: Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63: 1759-1763, 2003. (Pubitemid 36469314)
31. Tokutake Y, Matsumoto T, Watanabe T, Maeda S, Tahara H, Sakamoto S, Niida H, Sugimoto M, Ide T and Furuichi Y: Extra-chromosomal telomere repeat DNA in telomerase-negative immortalized cell lines. Biochem Biophys Res Commun 247: 765-772, 1998. (Pubitemid 28418466)
32. Reddel RR: Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett 194: 155-162, 2003. (Pubitemid 36577326)
33. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR and Royds JA: Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361: 836-838, 2003. (Pubitemid 36331849)
34. Bryan TM and Reddel RR: SV40-induced immortalization of human cells. Crit Rev Oncog 5: 331-357, 1994.
35. Motokura T and Arnold A: Cyclins and oncogenesis. Biochim Biophys Acta 1155: 63-78, 1993.
36. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
37. Saretzki G, Petersen S, Petersen I, Kolble K and von Zglinicki T: hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines. Cancer Lett 176: 81-91, 2002. (Pubitemid 34085073)
38. Kim JH, Lee GE, Kim JC, Lee JH and Chung IK: A novel telomere elongation in an adriamycin-resistant stomach cancer cell line with decreased telomerase activity. Mol Cells 13: 228-236, 2002.